Unlock DLL3 Target Potential with CUSABIO's High-Quality Proteins and Antibodies

As an important member of the Notch ligand family, Delta-Like Ligand 3 (DLL3) has emerged as a promising target in cancer therapy. In recent years, the successful development of drugs such as ZL-1310 by Zai Lab and Tarlatamab by Amgen has positioned DLL3 as a key therapeutic target for small cell lung cancer (SCLC) and other neuroendocrine tumors.

Currently, drug development targeting DLL3 is in a rapid growth phase. Some of the ongoing pipelines are summarized in the table below:

Drug Name	Research Institutions	Drug Type	Indications	Highest Development Stage
89Zr-DFO-SC16.56	Memorial Sloan Kettering Cancer Center	Antibody conjugated nuclide \| diagnostic radiagents	Small cell lung cancer \| neuroendocrine tumor	Phase I
ABD-147	Abdera Therapeutics, Inc.	Nanoantibodies \| radiation drugs for therapy	Large cell neuroendocrine lung cancer \| small cell lung cancer \| broad stage small cell lung cancer \| non-small cell lung cancer	Phase I
IBI3009	Cinda Biopharmaceutical (Suzhou) Co., Ltd	ADC	Advanced malignant solid tumor \| neuroendocrine carcinoma \| small cell lung cancer	Phase I
LB2102	Novartis AG \| Legend Biotech USA, Inc.	autologous CAR-T	Broad-stage small cell lung cancer \| undifferentiated large cell lung cancer	Phase I
SHR-4849	Shanghai hengrui pharmaceutical co., LTD. \| Suzhou ShengDi biological medicine co., LTD	ADC	Advanced malignant solid tumor	Phase I
α-PD-L1/4-1BB DLL3 CAR-T(Brilliant Pharmaceutical)	Chengdu Bete Pharmaceutical Co., Ltd	CAR-T	Broad-stage small-cell lung cancer	Phase I

To support your DLL3-targeted drug development, CUSABIO has launched a range of high-quality DLL3 recombinant proteins and antibodies, covering human, Macaca fascicularis, and other species. These products are designed to assist in exploring the target mechanism and potential clinical applications.

● DLL3 Recombinant Protein